Lineage Cell Therapeutics
LCTX
LCTX
115 hedge funds and large institutions have $105M invested in Lineage Cell Therapeutics in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
8% more funds holding
Funds holding: 106 → 115 (+9)
2.64% more ownership
Funds ownership: 38.32% → 40.96% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
115
Holding in Top 10
3
Calls
$121K
Puts
$4K
Top Buyers
| 1 | +$2.16M | |
| 2 | +$1.5M | |
| 3 | +$964K | |
| 4 |
Jane Street
New York
|
+$683K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$597K |
Top Sellers
| 1 | -$237K | |
| 2 | -$220K | |
| 3 | -$120K | |
| 4 |
BlackRock
New York
|
-$111K |
| 5 |
Lazard Asset Management
New York
|
-$104K |